Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04356300
Other study ID # 2020005
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date September 1, 2020
Est. completion date September 1, 2030

Study information

Verified date May 2020
Source Fujian Medical University
Contact Yi-Kun Jiang
Phone 86-14759926068
Email 869582567@qq.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Multiple organ dysfunction syndrome (MODS) after surgical repaired for acute type A aortic dissection (ATAAD) is a life-threatening condition. In this study, patients who undergoing surgical repaired of ATAAD immediately or presenting sever MODS after surgical repaired of acute type A aortic dissection will be treated with umbilical cord-derived mesenchymal stem cell.


Description:

Multiple organ dysfunction syndrome (MODS) are common debilitating complications after surgical repaired for ATAAD. MODS is one of the chief causes of post-operative death for acute type A aortic dissection (ATAAD) patients, and it was reported that MODS accounted for more than half of the death after surgery for ATAAD. Despite recent advance in surgical technique, mortality rate remains high in such critical care conditions. In animal models, studies have demonstrated the beneficial effects of MSCs with respect to ischemia-reperfusion injury of heart, lungs, kidney, brains and livers. Several pilot studies have provided evidence that MSC may be effective in treating critically ill patients with traumatic brain injury, acute renal failure, or acute respiratory distress syndrome. There is increasing evidence that MSCs function in a paracrine manner. Exosomes have been reported to activate signaling pathways by binding to receptors. Compared with mesenchymal stem cells, exosomes are more stable and storable and no risk of aneuploidy. The possibility of immune rejection after allogeneic administration of exosomes is lower and can provide alternative treatment for a variety of diseases.

The trial contains two parts:

Part one (prevention scheme):to explore the safety and efficacy of exosome of MSC, the investigators will recruit patients who are diagnosed with ATAAD, and 15 participants will be administrated intravenously with exosome of MSC immediately after ascending aortic replacement combined with open placement of triple branched stent graft while other 15 not. Then the investigators will monitor participants' MODS related biochemical indexes, sequential organ failure assessment (SOFA) scores, comparing to those don't be treated with exosome of MSC.

Phase two (treatment scheme): for patients presenting severe MODS (SOFA score≥10) after ascending aortic replacement combined with open placement of triple-branched stent graft, the investigators will randomly use exosome of MSC to 15 of participants while other 15 not. Then the investigators will monitor participants' MODS related biochemical indexes, SOFA scores, comparing to those don't be treated with MSC. The dosage of the exosome of MSC was determined on the basis of the previous clinical studies, which is 180mg once a time and administrated intravenously.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 60
Est. completion date September 1, 2030
Est. primary completion date September 1, 2021
Accepts healthy volunteers No
Gender All
Age group 20 Years to 80 Years
Eligibility Inclusion Criteria:

- Part 1:

- Patients who are diagnosed with ATAAD and received emergency surgery with ascending aortic replacement combined with open placement of triple-branched stent graft

- elder than 60 years old

- Preoperative PaO2/FiO2 = 400mmHg, platelets = 150*109/L, bilirubin= 20µmol/L, no hypotension (without vasoactive drugs), Glasgow Coma Score Scale = 15, creatine =110µmol/L

Part 2:

- Patients who are diagnosed with ATAAD and received emergency surgery with ascending aortic replacement combined with open placement of triple-branched stent graft

- Patients who have failure of at least 2 organs

- Patients who meet the criteria as below:

sequential organ failure assessment score (SOFA) = 10

Exclusion Criteria:

- • uncontrollable underlying disease life expectancy of less than 4 days history of long-term corticosteroid use during the past 6 months.

- The pre-operative computer tomography angiography(CTA) demonstrate the visceral arteries are involved

- pre-existing severe disease of any major organs

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Exosome of MSC
Exosome of MSC at a dose of 150mg will be given intravenously to patients once a day for 14 times.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Fujian Medical University

Outcome

Type Measure Description Time frame Safety issue
Primary survival after intervention comparing survival ratio in hospital(6 months post-intervention) between groups. Up to 6 month
Primary sequential organ failure assessment score Compare the change of sequential organ failure assessment score between groups. Scores ranged from 0 to 24. The higher the score, the worse the prognosis. Up to 6 months
Primary interleukin-6 Compare the change of concentration of interleukin( IL)-6 between groups. Early 3 days
Primary The number of allergic reactions Allergic reactions are mostly manifested as skin flushing, rash and itching. Severe allergic reactions such as chills, high fever and anaphylactic shock are rare. Up to 6 months
Primary The number of people who get cancer The number of people diagnosed with cancer after treatment Up to 2 years
Secondary the effects on kidney function the therapeutic effects in the improvement of kidney function, as indicated by Scr level. Up to 6 months
Secondary the effects on liver function the therapeutic effects in the improvement of liver function, as indicated by bilirubin levels. Up to 6 months
Secondary the effects on lung function the therapeutic effects in the improvement of lung function, as indicated by oxygenation index. Up to 6 months
Secondary the effects on coagulation function the therapeutic effects in the improvement of coagulation function, as indicated by blood platelet count. Up to 6 months
Secondary the effects on central nervous system The Glasgow coma scale has a maximum score of 15 and a minimum score of 3, indicating consciousness. 12-14 was classified as mild consciousness disorder; 9-11 was classified as moderate disturbance of consciousness; A score below 8 is coma; The lower the score, the greater the disturbance of consciousness. Up to 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT02906345 - TPE in Septic Patients and Influence on Organ Failure N/A
Completed NCT01937676 - LDH as a Biochemical Biomarker to Predict Organ Failure in the Emergency Department Setting N/A
Terminated NCT03895853 - Early Metabolic Resuscitation for Septic Shock Phase 2
Recruiting NCT04094428 - Burden, Mortality and Supply Costs in Intensive Care Unit Patients
Recruiting NCT02587273 - The Pharmacokinetics of Fentanyl in Intensive Care Patients Phase 4
Recruiting NCT02265419 - Use of Extracorporeal Treatment With the Cytosorb-Adsorber for the Reduction of SIRS in Heart Surgery Patients N/A
Completed NCT01810328 - A Validation of a Genomics Based Prognostic in Severe Trauma N/A
Not yet recruiting NCT06371677 - Polish Nationwide Register of Hospitalized Patients in Cardiac Intensive Care Units
Recruiting NCT05182723 - Evaluation of the Effectiveness of Extracorporeal Methods for Removing Mediators of Systemic Inflammation N/A
Completed NCT00257231 - Inflammation and the Host Response to Injury (Trauma)
Recruiting NCT04306419 - Observational Trial on Cytokine Adsorption in Sepsis
Completed NCT02998931 - Trial of Enteral Glutamine on Clinical Outcomes in Critically Ill Patients Phase 3
Not yet recruiting NCT06340269 - Feasibility Pilot Study to Evaluate the Safety and Performance of the MEX-CD1 Medical Device in ACLF N/A
Not yet recruiting NCT01828372 - Quantification of Drugs and Their Degradation Products N/A
Completed NCT00118664 - Patient Plasma Response and Outcome in Septic Shock With Thrombocytopenia Associated Multiple Organ Failure in Children N/A
Completed NCT02706314 - Impact of Human Blood Serum From Critically Ill Patients on Human Colon Neuronal Networks.
Completed NCT02455180 - Pharmacokinetics of Two Different High-dose Regimens of Intravenous Vitamin C in Critically Ill Patients Phase 4
Recruiting NCT02095444 - Using Human Menstrual Blood Cells to Treat Acute Lung Injury Caused by H7N9 Bird Flu Virus Infection Phase 1/Phase 2
Active, not recruiting NCT02858778 - Timing of Acute Palliative Care Consultation in Critically Ill Patients N/A
Recruiting NCT01363635 - Severe Sepsis/Septic Shock on Admission to the General Surgical ICU